Comparative effectiveness of clozapine and standard antipsychotic treatment in adults with schizophrenia

American Journal of Psychiatry

Volumn 173, Issue 2, 2016, Pages 166-173

  Stroup, T Scott ^a   Gerhard, Tobias ^a   Crystal, Stephen ^a   Huang, Cecilia ^a   Olfson, Mark ^a  

^a NEW YORK STATE PSYCHIATRIC INSTITUTE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CLOZAPINE; NEUROLEPTIC AGENT;

ADULT; ARTICLE; AUTOMUTILATION; COHORT ANALYSIS; DIABETES MELLITUS; DRUG EFFICACY; DRUG SAFETY; DRUG USE; DRUG WITHDRAWAL; FEMALE; HOSPITAL ADMISSION; HUMAN; HYPERLIPIDEMIA; INTESTINE OBSTRUCTION; MAJOR CLINICAL STUDY; MALE; MORTALITY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SCHIZOPHRENIA; TREATMENT OUTCOME; VENOUS THROMBOEMBOLISM; COMPARATIVE STUDY; FACTUAL DATABASE; HOSPITALIZATION; HYPERLIPIDEMIAS; INTESTINAL OBSTRUCTION; MEDICAID; MENTAL HEALTH SERVICE; MIDDLE AGED; PROPORTIONAL HAZARDS MODEL; PSYCHOTIC DISORDERS; STATISTICAL MODEL; STATISTICS AND NUMERICAL DATA; UNITED STATES; UTILIZATION;

ADULT; ANTIPSYCHOTIC AGENTS; CLOZAPINE; COHORT STUDIES; DATABASES, FACTUAL; DIABETES MELLITUS; FEMALE; HOSPITALIZATION; HUMANS; HYPERLIPIDEMIAS; INTESTINAL OBSTRUCTION; LOGISTIC MODELS; MALE; MEDICAID; MENTAL HEALTH SERVICES; MIDDLE AGED; PROPORTIONAL HAZARDS MODELS; PSYCHOTIC DISORDERS; RETROSPECTIVE STUDIES; SCHIZOPHRENIA; TREATMENT OUTCOME; UNITED STATES;

EID: 84957608746     PISSN: 0002953X     EISSN: 15357228     Source Type: Journal    
DOI: 10.1176/appi.ajp.2015.15030332     Document Type: Article

References (36)

1. World Health Organization: The Global Burden of Disease. Geneva, WHO Press, 2008
2. Conley RR, Kelly DL: Management of treatment resistance in schizophrenia. Biol Psychiatry 2001; 50:898-911
3. Duggan A, Warner J, Knapp M, et al: Modelling the impact of clozapine on suicide in patients with treatment-resistant schizophrenia in the UK. Br J Psychiatry 2003; 182:505-508
4. Kelly DL, Kreyenbuhl J, Dixon L, et al: Clozapine underutilization and discontinuation in African Americans due to leucopenia. Schizophr Bull 2007; 33:1221-1224
5. Aberg K, Adkins DE, Bukszár J, et al: Genomewide association study of movement-related adverse antipsychotic effects. Biol Psychiatry 2010; 67:279-282
6. Davies LM,DrummondMF: Assessment of costs and benefits of drug therapy for treatment-resistant schizophrenia in the United Kingdom. Br J Psychiatry 1993; 162:38-42
7. Kane J, Honigfeld G, Singer J, et al: Clozapine for the treatmentresistant schizophrenic: a double-blind comparison with chlorpromazine. Arch Gen Psychiatry 1988; 45:789-796
8. Leucht S, Cipriani A, Spineli L, et al: Comparative efficacy and tolerability of 15 antipsychotic drugs in schizophrenia: a multipletreatments meta-analysis. Lancet 2013; 382:951-962
9. Meltzer HY, Alphs L, Green AI, et al: Clozapine treatment for suicidality in schizophrenia: International Suicide Prevention Trial (InterSePT). Arch Gen Psychiatry 2003; 60:82-91
10. Honigfeld G, Arellano F, Sethi J, et al: Reducing clozapine-related morbidity and mortality: 5 years of experience with the Clozaril National Registry. J Clin Psychiatry 1998; 59(suppl 3):3-7
11. Downs J, Zinkler M: Clozapine: national review of postcode prescribing. Psychiatrist 2007; 31:384-387
12. Stroup TS, Gerhard T, Crystal S, et al: Geographic and clinical variation in clozapine use in the United States. Psychiatr Serv 2014; 65: 186-192
13. McEvoy JP, Lieberman JA, Stroup TS, et al: Effectiveness of clozapine versus olanzapine, quetiapine, and risperidone in patients with chronic schizophrenia who did not respond to prior atypical antipsychotic treatment. Am J Psychiatry 2006; 163:600-610
14. Tiihonen J, Wahlbeck K, Lönnqvist J, et al: Effectiveness of antipsychotic treatments in a nationwide cohort of patients in community care after first hospitalisation due to schizophrenia and schizoaffective disorder: observational follow-up study. BMJ 2006; 333:224
15. Tiihonen J, Haukka J, Taylor M, et al: A nationwide cohort study of oral and depot antipsychotics after first hospitalization for schizophrenia. Am J Psychiatry 2011; 168:603-609
16. Hayes RD, Downs J, Chang CK, et al: The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders. Schizophr Bull 2015; 41:644-655
17. KiviniemiM, Suvisaari J, Koivumaa-Honkanen H, et al: Antipsychotics and mortality in first-onset schizophrenia: prospective Finnish register study with 5-year follow-up. Schizophr Res 2013; 150:274-280
18. Tiihonen J, Lönnqvist J, Wahlbeck K, et al: 11-year follow-up of mortality in patients with schizophrenia: a population-based cohort study (FIN11 study). Lancet 2009; 374:620-627
19. Crump C, Winkleby MA, Sundquist K, et al: Comorbidities and mortality in persons with schizophrenia: a Swedish national cohort study. Am J Psychiatry 2013; 170:324-333
20. Kane JM, Leucht S, Carpenter D, et al: The expert consensus guideline series. Optimizing pharmacologic treatment of psychotic disorders: introduction: methods, commentary, and summary. J Clin Psychiatry 2003; 64(suppl 12):5-19
21. Leucht S,McGrath J,White P, et al: Carbamazepine for schizophrenia and schizoaffective psychoses. Cochrane Database Syst Rev 2002; (3):CD001258
22. Geddes JR, Goodwin GM, Rendell J, et al: Lithium plus valproate combination therapy versus monotherapy for relapse prevention in bipolar I disorder (BALANCE): a randomised open-label trial. Lancet 2010; 375:385-395
23. Lieberman JA, Stroup TS, McEvoy JP, et al: Effectiveness of antipsychotic drugs in patients with chronic schizophrenia. N Engl J Med 2005; 353:1209-1223
24. Bobo WV, Cooper WO, Stein CM, et al: Positive predictive value of a case definition for diabetesmellitus using automated administrative health data in children and youth exposed to antipsychotic drugs or control medications: a Tennessee Medicaid study. BMC Med Res Methodol 2012; 12:128
25. Olfson M, Marcus SC, Corey-Lisle P, et al: Hyperlipidemia following treatment with antipsychotic medications. Am J Psychiatry 2006; 163:1821-1825
26. Sykes J, Vergese S: Medicaid Analytic Extract Date of Death (MAX DOD) Master File, 2009 Update. Washington, DC, Mathematica Policy Reearch, 2013
27. Brookhart MA, Stürmer T, Glynn RJ, et al: Confounding control in healthcare database research: challenges and potential approaches. Med Care 2010; 48(suppl):S114-S120
28. Parson LS: Using SAS Software to Perform a Case-Control Match on Propensity Score in an Observational Study. Seattle,Wash, SAS, 2001
29. Mamdani M, Sykora K, Li P, et al: Reader's guide to critical appraisal of cohort studies: 2 Assessing potential for confounding. BMJ 2005; 330:960-962
30. Cummings P, McKnight B, Greenland S: Matched cohort methods for injury research. Epidemiol Rev 2003; 25:43-50
31. Detry MA, Lewis RJ: The intention-to-treat principle: how to assess the true effect of choosing amedical treatment. JAMA2014 312:85-86
32. Department of Health andHumanServices: http://www. resdac. org/ sites/resdac. org/files/LDS-DataUseAgreement. pdf
33. Freudenreich O, Henderson DC, Sanders KM, et al: Training in a clozapine clinic for psychiatry residents: a plea and suggestions for implementation. Acad Psychiatry 2013; 37:27-30
34. Chakos M, Lieberman J, Hoffman E, et al: Effectiveness of secondgeneration antipsychotics in patients with treatment-resistant schizophrenia: a review and meta-analysis of randomized trials. Am J Psychiatry 2001; 158:518-526
35. Kane JM, Honigfeld G, Singer J, et al: Clozapine in treatmentresistant schizophrenics. Psychopharmacol Bull 1988; 24:62-67
36. Manuel JI, Essock SM,WuY, et al: Factors associated with initiation on clozapine and on other antipsychotics among Medicaid enrollees. Psychiatr Serv 2012; 63:1146-1149